HIMS Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings has a net margin of 8.44% compared to Hims & Hers Health's net margin of -8.15%. Hims & Hers Health's return on equity of 37.84% beat Grove Collaborative Holdings's return on equity of -164.34%.

Hims & Hers Health has a consensus price target of $49.80, signalling downside risk potential of -10.25%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.10 which suggests that it could grow by 82.61%. Given that Grove Collaborative Holdings has higher upside potential than Hims & Hers Health, analysts believe Grove Collaborative Holdings is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 2.094, which suggesting that the stock is 109.43% more volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $586M, which are larger than Grove Collaborative Holdings quarterly revenues of $43.5M. Hims & Hers Health's net income of $49.5M is higher than Grove Collaborative Holdings's net income of -$3.5M. Notably, Hims & Hers Health's price-to-earnings ratio is 80.41x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 7.50x versus 0.22x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Kenvue has a net margin of 8.44% compared to Hims & Hers Health's net margin of 8.61%. Hims & Hers Health's return on equity of 37.84% beat Kenvue's return on equity of 10.32%.

Hims & Hers Health has a consensus price target of $49.80, signalling downside risk potential of -10.25%. On the other hand Kenvue has an analysts' consensus of $24.54 which suggests that it could grow by 14.39%. Given that Kenvue has higher upside potential than Hims & Hers Health, analysts believe Kenvue is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 2.094, which suggesting that the stock is 109.43% more volatile than S&P 500. In comparison Kenvue has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue offers a yield of 3.82% to investors and pays a quarterly dividend of $0.21 per share. Hims & Hers Health pays -- of its earnings as a dividend. Kenvue pays out 150.68% of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $586M, which are smaller than Kenvue quarterly revenues of $3.7B. Hims & Hers Health's net income of $49.5M is lower than Kenvue's net income of $322M. Notably, Hims & Hers Health's price-to-earnings ratio is 80.41x while Kenvue's PE ratio is 39.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 7.50x versus 2.70x for Kenvue. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of 8.44% compared to Hims & Hers Health's net margin of -14.51%. Hims & Hers Health's return on equity of 37.84% beat The Beauty Health's return on equity of -66.39%.

Hims & Hers Health has a consensus price target of $49.80, signalling downside risk potential of -10.25%. On the other hand The Beauty Health has an analysts' consensus of $1.76 which suggests that it could grow by 15.03%. Given that The Beauty Health has higher upside potential than Hims & Hers Health, analysts believe The Beauty Health is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 2.094, which suggesting that the stock is 109.43% more volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $586M, which are larger than The Beauty Health quarterly revenues of $69.6M. Hims & Hers Health's net income of $49.5M is higher than The Beauty Health's net income of -$10.1M. Notably, Hims & Hers Health's price-to-earnings ratio is 80.41x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 7.50x versus 0.63x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.